Disease-free survival landmark analysis: a potential critical endpoint in triple-negative breast cancer.

ABSTRACT: Taxanes plus carboplatin (TP) regimen may be an acceptable alternative adjuvant chemotherapy strategy in patients with triple-negative breast cancer (TNBC); however, the difference with the anthracycline-based regimen is yet to be clarified. Therefore, this study aimed to assess the difference between platinum-based and anthracycline-based regimens in prolonging the survival time in TNBC. Using exploratory landmark analysis, we found that the platinum-based TP regimen offers a longer disease-free survival (DFS) than the anthracycline-based regimen in TNBC patients with a DFS of > 4 years.

SUBMITTER: Zheng F 

PROVIDER: S-EPMC9513960 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature